Sign in
CompletedNo phase

Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery

Key facts

Who runs it
DALIM TISSEN Co., Ltd.
Where
South Korea3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
130 people enrolled
Started
22 Oct 2024
Ended
18 Aug 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CollaStat®
  • Floseal®
Record updated
21 January 2026

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • An individual who has voluntarily signed the written consent form for participating in the research as a trial subject
  • Patients aged 20 or older
  • Patients who are able to participate throughout the entire clinical trial period
  • Patient scheduled to have spinal surgery due to spinal stenosis, spinal tumor, injury, etc
  • Patients for whom hemostasis is difficult to achieve using standard procedures
  • Patients with grade 3 or higher bleeding * Grade 4 or 5 bleeding is reduced to grade 3 by normal procedures (compression, sutures, electrosurgical scalpel, etc.)

Who cannot take part

  • Individuals with hypersensitivity to bovine-, porcine-, or animal-derived materials
  • Patients with active infections at the surgical site
  • Pregnant women or those planning to become pregnant within 1 month after application of the collagen-based hemostat
  • Individuals deemed inappropriate for participation by the investigators
  • Patients who are using treatments that may affect the test results
  • Patients with contraindications to the use of local hemostatic materials

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial evaluates the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compares this investigational product with an existing hemostatic agent to assess whether it performs equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who require spinal surgery will be enrolled. The hemostat will be applied intraoperatively when grade 3 bleeding is observed. The study aims to determine how well the product works in achieving hemostasis and its safety when it is used during surgery.

The 2 groups in the trial

  • Study GroupTreatment being tested

    Group applied with CollaStat®

    Treatment: Floseal®

  • Control GroupExisting treatment, for comparison

    Group applied with Floseal®

    Treatment: CollaStat®

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Clinical Trial to Assess Hemostasis by Applying Collagen-based Thrombin-containing Hemostat in Spinal Surgery
Record updated
21 January 2026